Advil-maker Haleon boosts sales by targeting consumers on weight-loss drugs

Haleon is leveraging increased GLP-1 weight-loss drug use by boosting sales of products intended to address associated side effects. The Advil maker is using strategic in-store placement to capture consumer demand linked to the GLP-1 boom, creating a modest growth opportunity for its consumer-health portfolio.